Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) today announced closing a definitive agreement with France-based Pierre Fabre following approval of the agreement by the European Commission on... Read More

Monday December 21, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, binimetinib, encorafenib

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) and France-based Pierre Fabre are collaborating to globally develop and commercialize Arrays late-stage novel oncology products, binimetinib and... Read More

Tuesday November 17, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, Ron Squarer, binimetinib, encorafenib